KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-3475A
MK-3475A-F84
Phase 3 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-3475A for Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS ≥50% is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS ≥50%
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active